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Abstract  
Introduction: The correlation between echocardiographic findings and the outcome of COVID-19 patients is 
still under debate.  
Objective: In the present study it has been endeavored to evaluate the cardiovascular condition of COVID-19 
patients using echocardiography and to assess the association of these findings with in-hospital mortality.  
Methods: In this retrospective cohort study, hospitalized COVID-19 patients from February to July 2020 with 
at least one echocardiogram were included. Data were extracted from patients’ medical records and the 
association between echocardiographic findings and in-hospital mortality was assessed using a multivariate 
model. The findings were reported as relative risk (RR) and 95% confidence interval (95% CI).  
Results: Data from 102 COVID-19 hospitalized patients were encompassed in the present study (63.7±15.7 
mean age; 60.8% male). Thirty patients (29.4%) died during hospitalization. Tricuspid regurgitation (89.2%), 
mitral valve regurgitation (89.2%), left ventricular (LV) diastolic dysfunction (67.6%), pulmonary valve 
insufficiency (PI) (45.1%) and LV systolic dysfunction (41.2%) were the most common findings on patients’ 
echocardiogram. The analyses of data showed that LV systolic (p=0.242) and diastolic (p=0.085) dysfunction 
was not associated with in-hospital mortality of COVID-19 patients, while the presence of PI (RR=1.85; 95% 
CI: 1.02 to 3.33; p=0.042) and patients’ age (RR=1.03; 95% CI: 1.01 to 1.08; p=0.009) were the two independent 
prognostic factors of in-hospital mortality. 
Conclusions: It seems that LV systolic and diastolic dysfunction was not associated with in-hospital mortality 
of COVID-19 patients. However, presence and PI and old age are possible prognostic factors of COVID-19 in-
hospital mortality. Therefore, using echocardiography might be useful in management of COVID-19. 
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INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), is the name of a novel coronavirus 
spread from Wuhan, China in December 2019. 
Since the declaration of COVID-19 pandemic in 
March 2020, until November 2020 more than 58 
million people have contracted the disease and 
there have been more than a million deaths, 
subsequently (1). Although, COVID-19 symptoms 
are mostly related to the lower respiratory tract 
infection, the disease expresses symptoms of many 
other organs’ involvement; such as the heart, brain, 
kidneys and the gastrointestinal tract. In addition 
to fever, dyspnea, cough and fatigue being the main 
symptoms, headache, nausea, vomiting, diarrhea 
and anosmia are also common symptoms of COVID-
19 (2-4). 
Since, there are several paper that showed 
troponin I levels in severe COVID-19 patients are 
much higher than non-severe cases, it seems that 
COVID-19 could affect cardiac muscle directly and 
cause cardiovascular disorders (5). Likewise, 
according to many different reports, vascular 
involvement such as pulmonary thromboembolism 
and stroke is also observed in COVID-19. Clinical 
assessment of patients shows that from every 5 
admitted patients, one has cardiac manifestations 
(6). This cardiac involvement could occur even 
without symptoms of pulmonary pneumonia (7). 
Existing literature on cardiovascular complications 
show that in 55% of COVID-19 patients undergoing 
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echocardiography, evidence of cardiovascular 
involvement is present. The most common findings 
on echocardiogram are right and left ventricular 
abnormalities, evidence of myocardial infarction 
and myocarditis. Nearly 15% of the patients had 
severe left-sided heart failure or tamponade (8); 
However, there are other studies suggesting 
different results. For example, in a study conducted 
on 74 COVID-19 patients it was found that right 
ventricular enlargement and right ventricular 
dysfunction were the most common abnormalities 
in the echocardiogram. Left ventricular function 
was normal or hyperdynamic in most of the 
patients (9).  
Therefore, it appears that in the setting of COVID-
19, abnormal findings on echocardiogram are 
relatively common. Regarding the life-threatening 
consequences of cardiovascular complications, it 
seems that performing echocardiography and 
examining its relationship with the outcome of the 
disease, could provide a better view of the disease 
prognosis.  
However, it is yet unclear which echocardiographic 
findings could be able to predict the outcome of the 
disease. In the present study an attempt was made 
to evaluate the most common echocardiography 
abnormalities of COVID-19 patients and to assess 
the relationship between the abnormalities and In-
hospital mortality.  
Methods 
Study design 
The present retrospective cohort study was 
performed on the records of COVID-19 patients 
who were admitted to Imam-Hossein Hospital in 
Tehran, Iran between March and June 2020. This 
study was approved by the ethics committee of 
Shahid Beheshti University of Medical Sciences and 
the researchers adhered to the principles of the 
Helsinki declaration. 
Subjects 
In the current study, all patients with COVID-19 
who had at least one echocardiogram during their 
hospital stay were included. COVID-19 infection 
was confirmed by a positive RT-PCR (polymerase 
chain reaction) test for severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) from a 
nasopharyngeal specimen. Exclusion criteria were 
insufficient information in the medical record, 
unrecorded outcome or pregnancy. During March 
and June 2020, 991 COVID-19 patients were 
admitted to the hospital, of whom 102 underwent 
echocardiography during hospitalization. The 
mean age of patients was 63.7 ± 15.7 years (60.8% 
male). 
Sample size calculation was performed based on 
the odds ratio of right ventricular (RV) dysfunction 
in echocardiography in prediction of in-hospital 
mortality. With considering of a odds ratio of 2.88, 
a 43% prevalence of RV dysfunction, with a power 
of 0.9 and an alpha of 0.05, the estimated sample 
size was achieved 77 cases.  
Data gathering 
Baseline and demographic characteristics of the 
patients were extracted from the hospital’s patient 
registration system and echocardiographic results 
were also included. At Imam Hossein hospital, 
echocardiography is performed by cardiologists 
who have at least 5 years of experience with 
echocardiography. Echocardiography was 
performed by a portable device (GE Vivid S5, USA) 
with a 6 MHz transducer. Patient echocardiogram 
results were reinterpreted by a cardiac specialist. 
Echocardiographic findings were left ventricular 
(LV) systolic dysfunction, right ventricular (RV) 
systolic dysfunction, LV diastolic dysfunction, RV 
diastolic dysfunction, left atrial enlargement, LV 
enlargement, right atrial enlargement, RV 
enlargement, dilated ascending aorta, aortic valve 
abnormality, pulmonary valve insufficiency (PI), 
tricuspid valve abnormality, mitral valve 
abnormalities, regional wall motion abnormality 
(RWMA), pulmonary artery pressure (PAP), LV 
hypertrophy, pericardial effusion, inferior vena 
cava size, inferior vena cava respiratory variation 
and ejection fraction. Finally, in-hospital mortality 
was recorded. 
Statistical analysis 
Continuous variables were described by mean ± 
standard deviation (SD), and Categorical variables 
were expressed as counts (percentage). 
Kolmogorov-Simonov test was used for checking 
normality assumption of data. Comparisons of 
means in normal data were done by T-test. Besides, 
for evaluating the association between categorical 
variables The Chi-square test and fisher exact test 
were used. In addition, a multivariate log binomial 
regression model was performed for investigating 
the association of death with echocardiogram 
factors (10). To avoid over-fitting in the 
multivariate model, just the factors which lead to p-
values less than 0.1 in univariate analysis, were 
selected for multivariate model. Final model was 
selected according to backward Wald. Findings 
were reported as relative risk ratio (RR) and its 
95% confidence interval (95% CI). Two-side P-
value less than 0.05 was considered statistically 
significant. Analyzing were done using the STATA 
14.0 Package. 
FRONTIERS IN EMERGENCY MEDICINE. 2021;5(4):e38 Sadeghi et al 
   
 
3 Copyright © 2021 Tehran University of Medical Sciences 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). 
Noncommercial uses of the work are permitted, provided the original work is properly cited. 
RESULTS 
Data of 102 patients were included. Thirty patients 
(29.4%) died during hospitalization. The deceased 
had a significantly higher mean age (p = 0.009), but 
the sex distribution (p = 0.320) and body mass 
index (p = 0.473) of the two groups were similar 
(Table 1).  
Echocardiographic findings in the studied patients 
were tricuspid regurgitation (89.2%), mitral valve 
regurgitation (89.2%), LV diastolic dysfunction 
(67.6%), PI (45.1%), LV systolic dysfunction 
(41.2%), RWMA (39.2%), abnormal PAP (36.3%), 
AI (35.3%), LV hypertrophy (17.6%), left atrial 
enlargement (16.7%), right atrial enlargement 
(16.7%), RV enlargement (14.7%), RV systolic 
dysfunction (12.7%), LV enlargement (11.8%) and 
pericardial effusion (11.8%).  
Univariate analyses showed that there was a 
significant relationship between age (p = 0.009) 
and aortic valve insufficiency (p = 0.045) with 
patient mortality. In addition, the relationship 
between patient mortality and PI (p = 0.051) was 
close to a significant level. While, LV systolic 
(p=0.242) and diastolic (p=0.085) dysfunction, RV 
systolic dysfunction (p=0.171), Left atrial 
enlargement (p=0.560), Left ventricular 
enlargement (p=0.744), Right atrial enlargement 
(p=0.244), right ventricular enlargement 
(p>0.999), dilated ascending aorta (p>0.999), 
thickened aortic valve (p=0.383), calcified aortic 
valve (p=0.751), aortic valve stenosis (p=0.294), 
tricuspid valve regurgitation (p=0.168), thickened 
mitral valve (p>0.999), calcified mitral valve 
(p=0.294), mitral valve regurgitation (0.727), 
RWMA (p=0.582), abnormal PAP (p=0.958), LV 
hypertrophy (p=0.123), pericardial effusion 
(p=0.329) and Inferior vena cava size (p=0.329) 
(Table 2).  
Therefore, by fitting a multivariate model, it was 
determined that the presence of PI (RR = 1.85; 95% 
CI: 1.02 to 3.33; p = 0.042) and the age of patients 
(RR = 1.03; 95% CI: 1.01 to 1.08; p = 0.009) are 






Age (year) 61.1±15.9 69.9±13.6 0.009 
Gender   
0.320 Female 26 (36.1) 14 (46.7) 
Male 46 (63.9) 16 (53.3) 
Body mass index   
0.473 
Underweight 1 (1.4) 1 (3.3) 
Normal 34 (47.2) 11 (36.7) 
Overweight 27 (37.5) 11 (38.7) 
Obese 10 (13.9) 7 (23.3) 
 
Table 2: Echocardiography findings of study COVID-19 







Left ventricular systolic dysfunction* 
No 45 (62.5) 15 (50.0) 0.242 
Yes 27 (37.5) 15 (50.0)  
Right ventricular systolic dysfunction 
No 65 (90.3) 24 (80.0) 0.171 
Mild to moderate 7 (9.7) 6 (20.0)  
Left ventricular diastolic dysfunction 
No 27 (37.5) 6 (20.0) 0.085 
Mild to severe 45 (62.5) 24 (80.0)  
 Left atrial enlargement 
No 59 (81.9) 26 (86.7) 0.560 
Mild to severe 13 (18.1) 4 (13.3)  
Left ventricular enlargement 
No 64 (88.9) 26 (86.7) 0.744a 
Mild to severe 8 (11.1) 4 (13.3)  
Right atrial enlargement 
No 58 (80.6) 27 (90.0) 0.244 
Mild to moderate 14 (19.4) 3 (10.0)  
Right ventricular enlargement 
No 61 (84.7) 26 (86.7) >0.999a 
Mild to severe 11 (15.3) 4 (13.3)  
Dilated ascending aorta 
No 69 (95.8) 29 (96.7) >0.999a 
Mild to severe 3 (4.2) 1 (3.3)  
Thickened aortic valve 
No 59 (81.9) 27 (90.0) 0.383a 
Yes 13 (18.1) 3 (10.0)  
Calcified aortic valve 
No 62 (86.1) 27 (90.0) 0.751a 
Yes 10 (13.9) 3 (10.0)  
Aortic valve insufficiency 
No 51 (70.8) 15 (50.0) 0.045 
Mild to moderate 21 (29.2) 15 (50.0)  
Aortic valve stenosis 
No 72 (100.0) 29 (96.7) 0.294a 
Severe 0 (0.0) 1 (3.3)  
Pulmonary valve insufficiency 
No 44 (61.1) 12 (40.0) 0.051 
Mild to moderate 28 (38.9) 18 (60.0)  
TR (Tricuspid valve regurgitation) 
No 10 (13.9) 1 (3.3) 0.168a 
Mild to severe 62 (86.1) 29 (96.7)  
Thickened mitral valve 
No 70 (97.2) 29 (96.7) >0.999a 
Yes 2 (2.8) 1 (3.3)  
Calcified mitral valve 
No 72 (100.0) 29 (96.7) 0.294a 
Yes 0 (0.0) 1 (3.3)  
Mitral valve regurgitation 
No 7 (9.7) 4 (13.3) 0.727a 
Mild to severe 65 (90.3) 26 (86.7)  
Regional wall motion abnormality 
No 45 (62.5) 17 (56.7) 0.582 
Yes 27 (37.5) 13 (43.3)  
Hypokinesia 
No 46 (64.8) 18 (62.1) 0.797 
Yes 25 (35.2) 11 (37.9)  
*Defined as ejection fraction with cut off of 50%.  
a Based on Fisher’s exact test. 
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independent prognostic factors of in-hospital 
mortality (Table 3).  
DISCUSSION 
This study showed that valvular disorders, LV 
diastolic dysfunction and LV systolic dysfunction 
are the most common disorders found in the 
electrocardiogram of patients with COVID-19, 
respectively. The analysis showed that LV systolic 
and diastolic dysfunction and RV dysfunction were 
not associated with COVID-19 related in-hospital 
mortality, while age and the presence of PI were 
found to be two independent predictors of in-
hospital mortality. Due to indistinct mechanism of 
cardiovascular damage by SARS-CoV-2, by direct 
attack to myocytes or secondary to hemodynamic 
and immunological consequences of the infection, 
such as volume overload in sepsis or cytokine 
storm, any abnormalities in accordance with 
patients’ mortality should be given special 
attention. Pulmonary valve insufficiency is 
generally associated with arrhythmias, right-sided 
heart dysfunction, and ultimately left heart 
damage. Ventricular arrhythmias or heart failure 
due to progressive ventricular defects can cause 
sudden cardiac death (11). The results of the 
present study are in line with the results of similar 
studies showing that the presence of abnormalities 
in the echocardiogram is associated with an 
increased risk of in-hospital mortality in COVID-19 
patients (12). COVID -19 infection can cause 
cardiac involvement even without pulmonary 
involvement (7). Through fever, increased activity 
of cytokines in the immune system, or ARDS in 
patients with pulmonary involvement, this 
infection could increase the pressure on the 
pulmonary circulation, putting additional burden 
on the cardiovascular system (13). Pulmonary 
valve insufficiency, especially in increased 
myocardial activity, increases the right ventricular 
diastolic pressure, thus impairing the left 
ventricular function. Left ventricular diastolic 
dysfunction is an independent cause of death in 
patients with normal ejection fraction (14). As a 
result, it can be concluded that even a small amount 
of pulmonary valve insufficiency - with 
mechanisms not fully understood - could create a 
setting for arrhythmia and reduced cardiac output 
due to the left and right ventricular dysfunctions. 
In the present study, it was found that the majority 
of patients with COVID-19 have echocardiographic 
abnormalities. In accordance with the present 
study, Dweck et al examined 1216 patients with 
COVID-19 and showed that in 55% of patients who 
undergo echocardiography, there is evidence of 
cardiac dysfunction. In this study, the most 
common abnormal echocardiographic findings 
were left ventricular dysfunction (39%) and right 
ventricular dysfunction (33%). In addition, it was 
found that about 15% of patients had severe 
ventricular dysfunction or tamponade (8). On the 
other hand, a study on 74 patients showed that 
right ventricular enlargement and right ventricular 
dysfunction are the most important abnormalities 
observed in the echocardiogram of COVID-19 
patients (9). Bursi et al. also studied 49 COVID-19 
patients with coronary artery disease, and 
concluded that the right ventricular failure is the 
most common abnormality observed in patients' 
echocardiograms and it is an independent 
prognostic factor of mortality in these patients(15). 
As it can be seen, the findings of studies on 
echocardiographic abnormalities in COVID-19 
patients differ considerably. The reason for this 
difference can be attributed to the unknown 
pathogenicity of SARS-CoV-2. Due to the fact that 
the receptor for this virus (angiotensin-converting 
enzyme 2) is widely distributed in various tissues 
of the body (16), it may cause a wide range of 
Table 2 (in continue): Echocardiography findings of study 








No 65 (91.5) 28 (96.6) 0.670a 
Yes 6 (8.5) 1 (3.3)  
Dyskinesia 
No 71 (100.0) 28 (96.6) 0.290a 
Yes 0 (0.0) 1 (3.4)  
Pulmonary artery pressure* 
Normal 46 (63.9) 19 (63.3) 0.958 
Abnorma 26 (36.1) 11 (36.7)  
Left ventricular hypertrophy 
No 62 (86.1) 22 (73.3) 0.123 
Mild to severe 10 (13.9) 8 (26.7)  
Pericardial effusion 
No 65 (72.2) 25 (27.8) 0.329a 
Normal or mild 7 (58.3) 5 (41.7)  
* Pulmonary artery pressure <30 mmHg was considered as 
normal, and value >30 mmHg was considered as abnormal. 
a Based on Fisher’s exact test 
 
Table 3: Multiple logistic regression of prognostic factors of 





95% CI P 
Pulmonary valve 
insufficiency 
1.85 1.02-3.33 0.042 
Age 1.03 1.01-1.04 0.009 
CI: confidence interval 
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disarrays, leading to significant differences in the 
study findings. But what is certain is that the 
majority of patients with COVID-19 have abnormal 
findings on echocardiography. 
Limitations 
Like many retrospective studies, this study has had 
limitations. The number of patients undergoing 
echocardiography was limited. Performing 
echocardiography on patients is indicated based on 
clinical evidence, such as increased shortness of 
breath, which point to a more severe form of the 
disease or a deterioration in patient status, 
increasing the likelihood of finding abnormal data 
in the samples. Also, due to the lack of patients’ 
echocardiogram prior to COVID-19 infection, it is 
not fully clear whether the observed abnormalities 
throughout the disease are acute, already present 
and have become more severe, or remained 
unchanged. Finally, the uncertainty of when to 
perform echocardiography in the course of the 
disease is a major limitation; this is because 
echocardiography may have been performed in the 
early stages of the disease and the patient may have 
developed symptoms of cardiac involvement later, 
or it may have been done too late with transient 
abnormalities gone away. 
CONCLUSIONS 
The findings of the present study showed that 
valvular insufficiency, LV diastolic dysfunction and 
LV systolic dysfunction are the most common 
abnormalities found in the electrocardiogram of 
patients with COVID-19, respectively. The analysis 
showed that LV systolic and diastolic dysfunction 
and RV dysfunction were not associated with 
COVID-19 related in-hospital mortality, while age 
and the presence of PI were found to be two 
independent prognostic factor ofCOVID-19 in-
hospital mortality. 
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